| - GRCh37:
- ChrMT:5782-13922
- GRCh38:
- ChrMT:5782-13922
| MT-ND4L, MT-ND5, MT-TC, MT-TD, MT-TR, MT-TS1, MT-TK, MT-TL2, MT-TS2, MT-TH, MT-TY, MT-ND4, MT-TG, MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-ND3 | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:5794-14876
- GRCh38:
- ChrMT:5794-14876
| MT-CYB, MT-ND3, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-TY, MT-ATP6, MT-ATP8, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-ND6, MT-TC, MT-TD, MT-CO1, MT-CO2, MT-CO3, MT-TE, MT-TK | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:6468-15586
- GRCh38:
- ChrMT:6468-15586
| MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-TD, MT-TE, MT-TG, MT-TH, MT-TK, MT-TL2, MT-TR, MT-TS1, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:7126-13988
- GRCh38:
- ChrMT:7126-13988
| MT-CO1, MT-CO2, MT-CO3, MT-ND3, MT-TD, MT-TG, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-ND4, MT-ND4L, MT-ND5, MT-TH, MT-TK, MT-ATP6, MT-ATP8 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8290-13040
- GRCh38:
- ChrMT:8290-13040
| MT-TR, MT-TS2, MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TK, MT-TL2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8350-13450
- GRCh38:
- ChrMT:8350-13450
| MT-TR, MT-TS2, MT-TK, MT-TL2, MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH | | Pearson syndrome | Pathogenic (Jun 12, 2019) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8470-13446
- GRCh38:
- ChrMT:8470-13446
| MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-CO3, MT-ND3, MT-ND4, MT-ATP6, MT-ATP8, MT-ND4L, MT-ND5 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8480-13440
- GRCh38:
- ChrMT:8480-13440
| MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TR, MT-TS2, MT-TG, MT-TH, MT-TL2 | | Pearson syndrome | Pathogenic (Jun 12, 2019) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8585-12965
- GRCh38:
- ChrMT:8585-12965
| MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8815-13722
- GRCh38:
- ChrMT:8815-13722
| MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8839-14895
- GRCh38:
- ChrMT:8839-14895
| MT-ATP6, MT-CO3, MT-CYB, MT-ND5, MT-ND6, MT-TE, MT-TG, MT-TS2, MT-ND3, MT-ND4, MT-ND4L, MT-TH, MT-TL2, MT-TR | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10105-15066
- GRCh38:
- ChrMT:10105-15066
| MT-CYB, MT-ND3, MT-ND4, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-ND4L, MT-ND5, MT-ND6, MT-TE | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10947-15537
- GRCh38:
- ChrMT:10947-15537
| MT-TL2, MT-TS2, MT-CYB, MT-ND4, MT-ND5, MT-ND6, MT-TE, MT-TH | | Pearson syndrome | Pathogenic | criteria provided, single submitter |
| - GRCh37:
- ChrMT:11263-15374
- GRCh38:
- ChrMT:11263-15374
| MT-ND6, MT-TE, MT-TH, MT-CYB, MT-ND4, MT-ND5, MT-TL2, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12114-14420
- GRCh38:
- ChrMT:12114-14420
| MT-ND4, MT-ND5, MT-ND6, MT-TH, MT-TL2, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12207
- GRCh38:
- ChrMT:12207
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Pathogenic (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12213
- GRCh38:
- ChrMT:12213
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12215
- GRCh38:
- ChrMT:12215
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12216
- GRCh38:
- ChrMT:12216
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12217
- GRCh38:
- ChrMT:12217
| MT-TS2 | | not provided, Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Conflicting interpretations of pathogenicity (Jul 29, 2020) | criteria provided, conflicting interpretations |
| - GRCh37:
- ChrMT:12218
- GRCh38:
- ChrMT:12218
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12223
- GRCh38:
- ChrMT:12223
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12230
- GRCh38:
- ChrMT:12230
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12231
- GRCh38:
- ChrMT:12231
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12234
- GRCh38:
- ChrMT:12234
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12235
- GRCh38:
- ChrMT:12235
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12236-12237
- GRCh38:
- ChrMT:12236-12237
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12236
- GRCh38:
- ChrMT:12236
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke, not specified, not provided
| Conflicting interpretations of pathogenicity (Jul 12, 2019) | criteria provided, conflicting interpretations |
| - GRCh37:
- ChrMT:12237
- GRCh38:
- ChrMT:12237
| MT-TS2 | | See cases, Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Conflicting interpretations of pathogenicity (Nov 7, 2019) | criteria provided, conflicting interpretations |
| - GRCh37:
- ChrMT:12237
- GRCh38:
- ChrMT:12237
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12239
- GRCh38:
- ChrMT:12239
| MT-TS2 | | Mitochondrial disease | Benign (Jan 10, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12245
- GRCh38:
- ChrMT:12245
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12246
- GRCh38:
- ChrMT:12246
| MT-TS2 | | not specified | Uncertain significance (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12246
- GRCh38:
- ChrMT:12246
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12247
- GRCh38:
- ChrMT:12247
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12248
- GRCh38:
- ChrMT:12248
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12250
- GRCh38:
- ChrMT:12250
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12255
- GRCh38:
- ChrMT:12255
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12258
- GRCh38:
- ChrMT:12258
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Pathogenic/Likely pathogenic (May 4, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- ChrMT:12258
- GRCh38:
- ChrMT:12258
| MT-TS2 | | Mitochondrial disease | Likely pathogenic (Mar 28, 2023) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12264
- GRCh38:
- ChrMT:12264
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Pathogenic/Likely pathogenic (May 4, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- ChrMT:12265
- GRCh38:
- ChrMT:12265
| MT-TS2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |